Published in
American Society of Clinical Oncology, Journal of Clinical Oncology, 15_suppl(32), p. 10071-10071, 2014
DOI: 10.1200/jco.2014.32.15_suppl.10071
Links
Tools
Fenretinide (4-HPR)/Lym-X-Sorb (LXS) oral powder plus ketoconazole in patients with high-risk (HR) recurrent or resistant neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) Consortium trial.
Journal article published in 2014 by
Barry James Maurer,
Julia Lynne Glade Bender,
Min Hee Kang,
Judith Villablanca,
Denice Wei,
Susan G. Groshen,
Shengping Yang,
Scarlett Czarnecki,
Meaghan P. Granger,
Howard M. Katzenstein,
Brian D. Weiss,
Katherine K. Matthay,
C. Patrick Reynolds,
Araz Marachelian
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 